Categories: World

Loxo’s targeted drug helps variety of advanced cancers in small study

The drug, larotrectinib, directly targets an acquired rather than inherited genetic defect called TRK fusions. In such patients, TRK genes abnormally attach to other genes, triggering accelerated cancer cell growth, according to Reuters.

If approved, the oral therapy would mark a major step toward treatment based on a patient’s or the cancer’s genetic traits rather than whether the disease originated in the lung, breast or elsewhere.

“What we’re seeing here is the original promise of precision medicine,” said Dr. David Hyman, chief of early drug development at Memorial Sloan Kettering Cancer Center in New York who led the study.

Merck & Co’s immunotherapy Keytruda last month became the first cancer drug to win U.S. approval based on specific genetic biomarkers regardless of the site of the original tumor.

The Loxo-funded larotrectinib study followed 50 TRK fusion-positive patients with more than a dozen different types of advanced cancer, including lung, pancreatic, breast and colon. Seventy-six percent of patients experienced significant tumor shrinkage, including complete remission in 12 percent.

“This is a real breakthrough,” said Hyman, who presented the data at the American Society of Clinical Oncology meeting in Chicago. He said the response rate exceeded expectations. “These are people who had no hope by and large.”

Researchers have yet to determine other key benchmarks of performance, including median overall survival, progression-free survival or duration of response as most patients were still alive and responding after one year.

Nearly all responders remained on the drug or received potentially curative surgery, with the longest ongoing response out to 25 months so far.

Loxo expects to apply late this year or early next for U.S. approval. The Food and Drug Administration granted larotrectinib its breakthrough designation, given to medicines it deems potentially important advances in serious diseases.

Up to 5,000 U.S. patients a year are diagnosed with the TRK defect, but Hyman said there could be more if testing becomes more common. Comprehensive genetic testing can detect TRK fusion and more specific tests are being developed.

Pediatric patients in the trial had a type of cancer called infantile fibrosarcoma, a disease with a high rate of TRK fusion. In some cases it can be cured with amputations or other disfiguring surgeries.

Researchers found that after treatment with larotrectinib, less radical limb-sparing surgery may be an option.

They were particularly struck by the drug’s lack of toxicity. No patients discontinued treatment due to side effects.

“This is a safety profile that feels to me more like a drug for a chronic medical condition like high blood pressure than a cancer therapy,” Hyman said.

Read also: New CRISPR Technique Targets and Destroys Cancer’s Command Center

Share
Published by
Nataly

Recent Posts

Lunar Leap: How Intuitive Machines Carved a Path for Commercial Space Exploration

The flight to the moon comes from a breakthrough in technology In a move that…

1 month ago

Edward Snowden and Bitcoin: A Revolutionary Perspective on Digital Currency

The Unprecedented Advancement of Digital Currency Edward Snowden, the notorious whistleblower and staunch advocate for…

1 month ago

Beyoncé Breaks New Ground: First Black Woman to Claim No. 1 on Hot Country Songs Chart with ‘Texas Hold ‘Em’

In the ever-evolving tapestry of music, where genres blend like colors on a canvas, Beyoncé…

1 month ago

Trump’s record $355M penalty: Navigating the legal maze and its broader implications

The Verdict Heard Round the World In a seismic shift, Donald Trump, the erstwhile President…

1 month ago

Emma Stone’s BAFTA 2024 Triumph: A Milestone in “Poor Things” Journey

Another high point for Emma Stone The 2024 EE BAFTA Film Awards marked a significant…

1 month ago

United Front Against AI Disruption: Tech Giants Forge Accord to Safeguard Elections

In an era where artificial intelligence (AI) holds the power to both innovate and destabilize,…

1 month ago